Bridgebio Oncology Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Bridgebio Oncology Therapeutics Inc 's ROA in the second quarter of 2026?
Bridgebio Oncology Therapeutics Inc recorded a cumulative net loss of $-182 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -34.1%.

However, within the Healthcare sector 503 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3785, from total ROA ranking in the first quarter of 2026 at 4460.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	290.87 %	107.54 %	1212.4 %	23643.41 %	10902.12 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-182	-154	-134	-115	-88
Return On Assets (TTM)	-34.1 %	-39.72 %	-40.15 %	-49.91 %	-79.85 %
BBOT's Total Ranking	# 3785	# 4460	#	#	#
Total Assets (TTM) in million	785	418	448	485	201
Seq. Total Assets Change	88 %	-6.85 %	-7.51 %	141.34 %	-0.18 %
Seq. Net Income Change	-	-	-	-	-

BBOT's 5 Years Annual ROA >> Back to BBOT Management Effectiveness >> Compare BBOT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 201
Sector	# 504
Overall	# 3780

Return On Assets Statistics
High	Average	Low
-39.81 %	-40.8 %	-42.17 %
(Mar 31 2026)		(Jun 30 2026)

Financial Statements
Bridgebio Oncology Therapeutics Inc 's Assets	$ 785 million	BBOT's Balance sheet
Bridgebio Oncology Therapeutics Inc 's Income	$ -56 million	Quarterly BBOT's Income Statement
BBOT's Income by Division		See BBOT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2023) FY 2024	FY	FY	FY
Y / Y Total Assets Change	134589.4 %	-	-	-	-
Total Assets in million	448	0	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-134	0	0	0	0
Annual Return On Assets	-29.9 %	-12.53 %	-	-	-

BBOT's 5 Years Annual ROA >> Back to BBOT Management Effectiveness >> Compare BBOT ROA to its Competitors

More Return On Assets Ratios
BBOT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BBOT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BBOT's Competitors
Subscribers only: Roa for Bridgebio Oncology Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for BBOT's Customers

You may also want to know
BBOT's Roi	BBOT's Inventory Turnover Ratio	BBOT's Growth Rates	BBOT's Dividend Comparisons
	BBOT's Profitability Ratios	BBOT's Asset Turnover Ratio	BBOT's Dividend Growth
BBOT's Roe	BBOT's Valuation Ratios	BBOT's Financial Strength Ratios	BBOT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T00:01:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.